Seattle Genetics to present SGN-75 phase I data at ESMO Congress

Oct 5 2010NewsGuard 100/100 Score

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that preliminary data from a phase I study of SGN-75 in relapsed and refractory non-Hodgkin lymphoma and metastatic renal cell carcinoma will be presented during a poster session at the 35th European Society for Medical Oncology (ESMO) Congress being held October 8-12, 2010 in Milan, Italy. SGN-75 is an antibody-drug conjugate (ADC) targeting CD70 that utilizes the company's proprietary technology.

“Targeting CD70 in Non-Hodgkin Lymphoma and Renal Cell Carcinoma: A Phase 1 Study of the Antibody-Drug Conjugate SGN-75”

Presentation details are as follows:

"Targeting CD70 in Non-Hodgkin Lymphoma and Renal Cell Carcinoma: A Phase 1 Study of the Antibody-Drug Conjugate SGN-75"

  • Monday, October 11, 2010
  • Poster # 532P, Hall 3
  • First author: Stephen M. Ansell, Mayo Clinic, Rochester, MN
Source:

: Seattle Genetics

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Study identifies six cancer susceptibility genes
New genetic model offers insights into breast cancer metastasis
Researchers use cerebrospinal fluid to unlock pathways in Alzheimer's disease
New drug strategy reverses resistance to immunotherapy in pancreatic cancer
Study links heart shape to genetic risk of cardiovascular diseases
Scientists uncover cerebrospinal fluid markers for Alzheimer's detection and treatment
Fermented kimchi may help combat obesity by regulating gut microbiota
Study shows how a single defective BRCA1 gene accelerates cancer development

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
New study highlights the importance of BMI in disease pathogenesis